Cincinnati Children's Hospital Medical Center Logo

July 2008

Loading...

Photograph of Cincinnati Children's Hospital Research building.Research Awards and Appointments

Yi Zheng, PhD, of the Division of Experimental Hematology and Cancer Biology, has been named Co-Principal Investigator of a National Institute of Neurological Disorders and Stroke R01 titled “Rac GTPases in the Mammalian Brain Development.” His total funding includes $480,000 over four years.

Hartmut Geiger, PhD, of the Division of Experimental Hematology and Cancer Biology, has been awarded a National Institute of Diabetes and Digestive and Kidney Diseases grant titled “Young Stem Cell Potential in Aged Mice.” It includes total funding of $412,500 over two years.

Qishen Pang, PhD, of the Division of Experimental Hematology and Cancer Biology, has been awarded the Leukemia and Lymphoma Society Scholar Award titled “Role of Tumor Necrosis Factor in Leukemogenesis.” It includes total funding of $550,000 over five years.

In March 2008, Gurjit Khurana Hershey, MD, PhD, director of the Institute for Personalized and Predictive Medicine, delivered the keynote Elliot R. Ellis Lecture at the annual meeting of the American Academy of Allergy, Asthma and Immunology. The lecture topic was “Genetic Factors Derivative from Birth Cohort Studies.”

Laurie Johnson, MD, of Emergency Services, has been accepted into the National Institute of Environmental Health Sciences funded training program Molecular Epidemiology in Children’s Environmental Health under the direction of Dr. Grace LeMasters at the University of Cincinnati.

The Division of Pediatric Orthopaedic Surgery has been chosen as one of 25 centers in the country to participate in BrAIST (Bracing in Adolescent Idiopathic Scoliosis Trial), the largest NIH-funded pediatric orthopaedic clinical trial. Charles Mehlman, DO, MPH, is the principal investigator for Cincinnati Children’s .

Simon Hogan, PhD, of the Division of Allergy and Immunology, was named principal investigator of a National Institutes of Health R01 grant, “Interleukin-9 Experimental Intestinal Anaphylaxis.” Funding is $375,000 each year for the next four years.